Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 10 (October)

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
   Lancet, 376(9747): 1164-74. [Abstract] [Full-text]
2. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
   Lancet, 376(9747): 1155-63. [Abstract] [Full-text]
3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
   Lancet, 376(9747): 1147-54. [Abstract] [Full-text]
4. Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
   Cell Prolif, 43(5): 480-93. [Abstract] [Full-text]
5. Integrins as therapeutic targets: lessons and opportunities.
   Nat Rev Drug Discov, 9(10): 804-20. [Abstract] [Full-text]
6. Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus–infected patients before and after antiretroviral therapy.
   J Infect Dis, 202(9): 1424-34. [Abstract] [Full-text]
7. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells.
   Toxicol Appl Pharmacol, 248(3): 259-68. [Abstract] [Full-text]
8. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux.
   J Vasc Surg, 52(4): 939-45. [Abstract] [Full-text]
9. A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect.
   Tumour Biol, 31(5): 523-32. [Abstract] [Full-text]
10. Combined contrast-enhanced ultrasound and rt-PA treatment is safe and improves impaired microcirculation after reperfusion of middle cerebral artery occlusion.
    J Cereb Blood Flow Metab, 30(10): 1712-20. [Abstract] [Full-text]
11. Photosensitive rash in association with porphyrin biosynthesis possibly induced by docetaxel and trastuzumab therapy in a patient with metastatic breast carcinoma.
    Jpn J Clin Oncol, 40(10): 989-91. [Abstract] [Full-text]
12. A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
    Jpn J Clin Oncol, 40(10): 992-4. [Abstract] [Full-text]
13. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Jpn J Clin Oncol, 40(10): 933-7. [Abstract] [Full-text]
14. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Jpn J Clin Oncol, 40(10): 954-60. [Abstract] [Full-text]
15. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Jpn J Clin Oncol, 40(10): 913-20. [Abstract] [Full-text]
16. Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus–infected patients before and after antiretroviral therapy.
    J Infect Dis, 202(9): 1424-34. [Abstract] [Full-text]
17. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells.
    Toxicol Appl Pharmacol, 248(3): 259-68. [Abstract] [Full-text]
18. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
    Br J Haematol, 151(1): 47-53. [Abstract] [Full-text]
19. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.
    Br J Haematol, 151(1): 70-83. [Abstract] [Full-text]
20. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial.
    JAMA, 304(13): 1455-64. [Abstract] [Full-text]
21. Breast cancer incidence and hormone replacement therapy in Canada.
    J Natl Cancer Inst, 102(19): 1489-95. [Abstract] [Full-text]
22. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
    J Natl Cancer Inst, 102(19): 1513-6. [Abstract] [Full-text]
23. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
    J Pediatr Hematol Oncol, 32(7): e268-71. [Abstract] [Full-text]
24. Treatment of pediatric Burkitt lymphoma in Turkey.
    J Pediatr Hematol Oncol, 32(7): e279-84. [Abstract] [Full-text]
25. Parathyroid adenoma and chondrosarcoma after treatment of pediatric Hodgkin disease.
    J Pediatr Hematol Oncol, 32(7): e294-6. [Abstract] [Full-text]
26. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Am J Clin Oncol, 33(5): 489-94. [Abstract] [Full-text]
27. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy.
    BJU Int, 106(7): 1017-20. [Abstract] [Full-text]
28. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
    Am J Clin Oncol, 33(5): 461-4. [Abstract] [Full-text]
29. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
    Am J Clin Oncol, 33(5): 432-7. [Abstract] [Full-text]
30. Population-based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma.
    Am J Clin Oncol, 33(5): 465-8. [Abstract] [Full-text]
31. Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study.
    Cancer, 116(20): 4833-9. [Abstract] [Full-text]
32. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment.
    Cancer, 116(20): 4849-56. [Abstract] [Full-text]
33. Front-line management of diffuse large B cell lymphoma.
    Curr Opin Oncol, 22(6): 642-5. [Abstract] [Full-text]
34. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.
    J Clin Oncol, 28(29): 4434-40. [Abstract] [Full-text]
35. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    J Clin Oncol, 28(29): 4513-20. [Abstract] [Full-text]
36. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
    J Clin Oncol, 28(29): 4417-24. [Abstract] [Full-text]
37. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    J Clin Oncol, 28(29): 4425-33. [Abstract] [Full-text]
38. TP53 mutation and survival in chronic lymphocytic leukemia.
    J Clin Oncol, 28(29): 4473-9. [Abstract] [Full-text]
39. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    J Clin Oncol, 28(29): 4500-6. [Abstract] [Full-text]
40. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial.
    Am Heart J, 160(4): 678-84. [Abstract] [Full-text]
41. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Am Heart J, 160(4): 635-41. [Abstract] [Full-text]
42. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
    Lancet Oncol, 11(10): 973-82. [Abstract] [Full-text]
43. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Lancet Oncol, 11(10): 934-41. [Abstract] [Full-text]
44. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
    Gynecol Oncol, 119(2): 212-6. [Abstract] [Full-text]
45. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
    Gynecol Oncol, 119(2): 217-24. [Abstract] [Full-text]
46. Diselenium, instead of disulfide, bonded analogs of conotoxins: novel synthesis and pharmacotherapeutic potential.
    Life Sci, 87(15): 451-6. [Abstract] [Full-text]
47. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.
    Cancer Invest, 28(9): 925-31. [Abstract] [Full-text]
48. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Gynecol Oncol, 119(2): 351-7. [Abstract] [Full-text]
49. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
    Cancer Invest, 28(9): 910-6. [Abstract] [Full-text]
50. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
    Gynecol Oncol, 119(2): 212-6. [Abstract] [Full-text]
51. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
    Gynecol Oncol, 119(2): 217-24. [Abstract] [Full-text]
52. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.
    Cancer Invest, 28(9): 925-31. [Abstract] [Full-text]
53. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Gynecol Oncol, 119(2): 351-7. [Abstract] [Full-text]
54. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
    Cancer Invest, 28(9): 910-6. [Abstract] [Full-text]
55. Binary mixing of micelles using Pluronics for a nano-sized drug delivery system.
    Colloids Surf B Biointerfaces, 82(1): 190-5. [Abstract] [Full-text]
56. Interaction of cationic phosphorus dendrimers (CPD) with charged and neutral lipid membranes.
    Colloids Surf B Biointerfaces, 82(1): 8-12. [Abstract] [Full-text]
57. Multidrug encapsulation by coaxial tri-capillary electrospray.
    Colloids Surf B Biointerfaces, 82(1): 104-10. [Abstract] [Full-text]
58. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization.
    Colloids Surf B Biointerfaces, 82(1): 118-25. [Abstract] [Full-text]
59. Smart swelling biopolymer microparticles by a microfluidic approach: synthesis, in situ encapsulation and controlled release.
    Colloids Surf B Biointerfaces, 82(1): 81-6. [Abstract] [Full-text]
60. Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20.
    Colloids Surf B Biointerfaces, 82(1): 18-24. [Abstract] [Full-text]
61. Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants.
    Colloids Surf B Biointerfaces, 82(1): 63-70. [Abstract] [Full-text]
62. Effects of fluid resuscitation with hypertonic saline dextrane or Ringer's acetate after nonhemorrhagic shock caused by pulmonary contusion.
    J Trauma, 69(4): 741-8. [Abstract] [Full-text]
63. Polytherapy increases the risk of infertility in women with epilepsy.
    Neurology, 75(15): 1351-5. [Abstract] [Full-text]
64. Use of retinal procedures in medicare beneficiaries from 1997 to 2007.
    Arch Ophthalmol, 128(10): 1335-40. [Abstract] [Full-text]
65. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
    Arch Ophthalmol, 128(10): 1273-9. [Abstract] [Full-text]
66. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
    Br J Cancer, 103(8): 1201-8. [Abstract] [Full-text]
67. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
    Br J Cancer, 103(8): 1163-72. [Abstract] [Full-text]
68. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Br J Cancer, 103(8): 1149-53. [Abstract] [Full-text]
69. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
    Br J Cancer, 103(8): 1173-81. [Abstract] [Full-text]
70. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Eur J Surg Oncol, 36(11): 1047-53. [Abstract] [Full-text]
71. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
    Eur J Surg Oncol, 36(11): 1061-5. [Abstract] [Full-text]
72. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
    Arch Intern Med, 170(18): 1678-85. [Abstract] [Full-text]
73. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy.
    Arch Intern Med, 170(18): 1648-54. [Abstract] [Full-text]
74. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Eur J Surg Oncol, 36(11): 1047-53. [Abstract] [Full-text]
75. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
    Eur J Surg Oncol, 36(11): 1061-5. [Abstract] [Full-text]
76. Managing medications in clinically complex elders: "There's got to be a happy medium".
    JAMA, 304(14): 1592-601. [Abstract] [Full-text]
77. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
    Gut, 59(11): 1527-34. [Abstract] [Full-text]
78. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.
    J Acquir Immune Defic Syndr, 55(3): e17-23. [Abstract] [Full-text]
79. Preventing mother to child transmission of HIV with highly active antiretroviral treatment in Tanzania--a prospective cost-effectiveness study.
    J Acquir Immune Defic Syndr, 55(3): 397-403. [Abstract] [Full-text]
80. Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries.
    J Acquir Immune Defic Syndr, 55(3): 287-9. [Abstract] [Full-text]
81. Long-term outcomes of a national expanded access program to antiretroviral therapy: the Chilean AIDS cohort.
    J Acquir Immune Defic Syndr, 55(3): 368-74. [Abstract] [Full-text]
82. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
    J Acquir Immune Defic Syndr, 55(3): 404-10. [Abstract] [Full-text]
83. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township.
    Am J Respir Crit Care Med, 182(8): 1080-5. [Abstract] [Full-text]
84. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
    Gut, 59(11): 1527-34. [Abstract] [Full-text]
85. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.
    J Acquir Immune Defic Syndr, 55(3): e17-23. [Abstract] [Full-text]
86. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Br J Haematol, 151(3): 221-31. [Abstract] [Full-text]
87. Preventing mother to child transmission of HIV with highly active antiretroviral treatment in Tanzania--a prospective cost-effectiveness study.
    J Acquir Immune Defic Syndr, 55(3): 397-403. [Abstract] [Full-text]
88. Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries.
    J Acquir Immune Defic Syndr, 55(3): 287-9. [Abstract] [Full-text]
89. Long-term outcomes of a national expanded access program to antiretroviral therapy: the Chilean AIDS cohort.
    J Acquir Immune Defic Syndr, 55(3): 368-74. [Abstract] [Full-text]
90. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
    J Acquir Immune Defic Syndr, 55(3): 404-10. [Abstract] [Full-text]
91. Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk?
    BJU Int, 106(9): 1298-302; discussion 1302. [Abstract] [Full-text]
92. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    BJU Int, 106(9): 1266-9. [Abstract] [Full-text]
93. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
    Cancer Chemother Pharmacol, 66(6): 1113-21. [Abstract] [Full-text]
94. Resistance to platinum-based chemotherapy in lung cancer cell lines.
    Cancer Chemother Pharmacol, 66(6): 1103-11. [Abstract] [Full-text]
95. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
    Cancer Chemother Pharmacol, 66(6): 1159-65. [Abstract] [Full-text]
96. The 'Butter Test' to guide effective tissue cleansing after high-pressure injection injury.
    J Plast Reconstr Aesthet Surg, 63(11): e792-5. [Abstract] [Full-text]
97. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
    Cancer Chemother Pharmacol, 66(6): 1087-93. [Abstract] [Full-text]
98. Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
    Cancer Chemother Pharmacol, 66(6): 1123-9. [Abstract] [Full-text]
99. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Cancer Chemother Pharmacol, 66(6): 1079-85. [Abstract] [Full-text]
100. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).
     Cancer Chemother Pharmacol, 66(6): 1013-7. [Abstract] [Full-text]
101. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
     Cancer Chemother Pharmacol, 66(6): 1051-7. [Abstract] [Full-text]
102. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
     Cancer Chemother Pharmacol, 66(6): 1019-29. [Abstract] [Full-text]
103. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
     Cancer Chemother Pharmacol, 66(6): 1113-21. [Abstract] [Full-text]
104. Resistance to platinum-based chemotherapy in lung cancer cell lines.
     Cancer Chemother Pharmacol, 66(6): 1103-11. [Abstract] [Full-text]
105. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
     Cancer Chemother Pharmacol, 66(6): 1159-65. [Abstract] [Full-text]
106. Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: consortium for Improving Survival of Lymphoma (CISL) study.
     Cancer Sci, 101(11): 2443-7. [Abstract] [Full-text]
107. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
     Cancer Sci, 101(11): 2470-5. [Abstract] [Full-text]
108. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin.
     Cancer Sci, 101(11): 2455-61. [Abstract] [Full-text]
109. The 'Butter Test' to guide effective tissue cleansing after high-pressure injection injury.
     J Plast Reconstr Aesthet Surg, 63(11): e792-5. [Abstract] [Full-text]
110. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
     Acta Oncol, 49(8): 1246-52. [Abstract] [Full-text]
111. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
     Cancer Chemother Pharmacol, 66(6): 1087-93. [Abstract] [Full-text]
112. Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
     Cancer Chemother Pharmacol, 66(6): 1123-9. [Abstract] [Full-text]
113. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
     Cancer Chemother Pharmacol, 66(6): 1079-85. [Abstract] [Full-text]
114. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).
     Cancer Chemother Pharmacol, 66(6): 1013-7. [Abstract] [Full-text]
115. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
     Cancer Chemother Pharmacol, 66(6): 1051-7. [Abstract] [Full-text]
116. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
     Cancer Chemother Pharmacol, 66(6): 1019-29. [Abstract] [Full-text]
117. In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes.
     Circulation, 122(16): 1578-87. [Abstract] [Full-text]
118. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
     J Clin Oncol, 28(30): 4601-8. [Abstract] [Full-text]
119. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
     J Clin Oncol, 28(30): 4554-61. [Abstract] [Full-text]
120. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
     J Clin Oncol, 28(30): 4649-57. [Abstract] [Full-text]
121. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
     J Clin Oncol, 28(30): 4568-74. [Abstract] [Full-text]
122. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.
     J Clin Oncol, 28(30): 4581-6. [Abstract] [Full-text]
123. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
     J Clin Oncol, 28(30): 4658-63. [Abstract] [Full-text]
124. Prevention of early vascular graft infection using regional antibiotic release.
     J Surg Res, 164(1): e185-91. [Abstract] [Full-text]
125. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
     J Clin Oncol, 28(30): 4635-41. [Abstract] [Full-text]
126. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
     J Clin Oncol, 28(30): 4621-9. [Abstract] [Full-text]
127. Timing of invasive treatment after fibrinolysis in ST elevation myocardial infarction--a meta-analysis of immediate or early routine versus deferred or ischemia-guided randomised controlled trials.
     Heart, 96(21): 1695-702. [Abstract] [Full-text]
128. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
     J Clin Oncol, 28(30): 4630-4. [Abstract] [Full-text]
129. Prevention of early vascular graft infection using regional antibiotic release.
     J Surg Res, 164(1): e185-91. [Abstract] [Full-text]
130. Timing of invasive treatment after fibrinolysis in ST elevation myocardial infarction--a meta-analysis of immediate or early routine versus deferred or ischemia-guided randomised controlled trials.
     Heart, 96(21): 1695-702. [Abstract] [Full-text]
131. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
     JAMA, 304(15): 1684-92. [Abstract] [Full-text]
132. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
     J Natl Cancer Inst, 102(20): 1547-56. [Abstract] [Full-text]
133. Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids.
     Crit Care Med, 38(11): 2117-24. [Abstract] [Full-text]
134. Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization.
     Crit Care Med, 38(11): 2095-102. [Abstract] [Full-text]
135. Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
     Clin Pharmacol Ther, 88(5): 660-7. [Abstract] [Full-text]
136. Determination of appropriate dosing of influenza drugs in pediatric patients.
     Clin Pharmacol Ther, 88(5): 704-7. [Abstract] [Full-text]
137. Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.
     Clin Pharmacol Ther, 88(5): 712-9. [Abstract] [Full-text]
138. Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
     Clin Pharmacol Ther, 88(5): 660-7. [Abstract] [Full-text]
139. Determination of appropriate dosing of influenza drugs in pediatric patients.
     Clin Pharmacol Ther, 88(5): 704-7. [Abstract] [Full-text]
140. Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids.
     Crit Care Med, 38(11): 2117-24. [Abstract] [Full-text]
141. Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization.
     Crit Care Med, 38(11): 2095-102. [Abstract] [Full-text]
142. Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.
     Clin Pharmacol Ther, 88(5): 712-9. [Abstract] [Full-text]
143. Microcystic lymphatic malformation (lymphangioma circumscriptum) treated using a minimally invasive technique of radiofrequency ablation and sclerotherapy.
     Dermatol Surg, 36(11): 1711-7. [Abstract] [Full-text]
144. Noninvasive extramammary Paget's disease treated with photodynamic therapy: case series from the Roswell Park Cancer Institute.
     Dermatol Surg, 36(11): 1718-24. [Abstract] [Full-text]
145. Microcystic lymphatic malformation (lymphangioma circumscriptum) treated using a minimally invasive technique of radiofrequency ablation and sclerotherapy.
     Dermatol Surg, 36(11): 1711-7. [Abstract] [Full-text]
146. Noninvasive extramammary Paget's disease treated with photodynamic therapy: case series from the Roswell Park Cancer Institute.
     Dermatol Surg, 36(11): 1718-24. [Abstract] [Full-text]
147. Does central venous oxygen saturation-directed fluid therapy affect postoperative morbidity after colorectal surgery? A randomized assessor-blinded controlled trial.
     Anesthesiology, 113(5): 1072-80. [Abstract] [Full-text]
148. Does primary tumour volumetry performed early in the course of definitive concomitant chemoradiotherapy for head and neck squamous cell carcinoma improve prediction of primary site outcome?
     Br J Radiol, 83(995): 964-70. [Abstract] [Full-text]
149. Does central venous oxygen saturation-directed fluid therapy affect postoperative morbidity after colorectal surgery? A randomized assessor-blinded controlled trial.
     Anesthesiology, 113(5): 1072-80. [Abstract] [Full-text]
150. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.
     Ophthalmology, 117(11): 2152-61.e1-2. [Abstract] [Full-text]
151. Feedback mechanisms including real-time electronic alerts to achieve near 100% timely prophylactic antibiotic administration in surgical cases.
     Anesth Analg, 111(5): 1293-300. [Abstract] [Full-text]
152. A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report.
     Am J Kidney Dis, 56(5): 832-41. [Abstract] [Full-text]
153. Case report: intraoperative management of extreme hemodilution in a patient with a severed axillary artery.
     Anesth Analg, 111(5): 1204-6. [Abstract] [Full-text]
154. Feedback mechanisms including real-time electronic alerts to achieve near 100% timely prophylactic antibiotic administration in surgical cases.
     Anesth Analg, 111(5): 1293-300. [Abstract] [Full-text]
155. A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report.
     Am J Kidney Dis, 56(5): 832-41. [Abstract] [Full-text]
156. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.
     Ophthalmology, 117(11): 2152-61.e1-2. [Abstract] [Full-text]
157. Case report: intraoperative management of extreme hemodilution in a patient with a severed axillary artery.
     Anesth Analg, 111(5): 1204-6. [Abstract] [Full-text]
158. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma.
     J Cancer Res Clin Oncol, 136(12): 1929-35. [Abstract] [Full-text]
159. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
     J Cancer Res Clin Oncol, 136(12): 1845-51. [Abstract] [Full-text]
160. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
     J Cancer Res Clin Oncol, 136(12): 1901-13. [Abstract] [Full-text]
161. Happy birthday cell penetrating peptides: already 20 years.
     Biochim Biophys Acta, 1798(12): 2177-81. [Abstract] [Full-text]
162. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake.
     Biochim Biophys Acta, 1798(12): 2304-14. [Abstract] [Full-text]
163. Optical small animal imaging in the drug discovery process.
     Biochim Biophys Acta, 1798(12): 2266-73. [Abstract] [Full-text]
164. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma.
     J Cancer Res Clin Oncol, 136(12): 1929-35. [Abstract] [Full-text]
165. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
     J Cancer Res Clin Oncol, 136(12): 1845-51. [Abstract] [Full-text]
166. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
     J Cancer Res Clin Oncol, 136(12): 1901-13. [Abstract] [Full-text]
167. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells.
     Biochim Biophys Acta, 1798(12): 2274-85. [Abstract] [Full-text]
168. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
     Biochim Biophys Acta, 1798(12): 2296-303. [Abstract] [Full-text]
169. Peptide-mediated protein delivery-which pathways are penetrable?
     Biochim Biophys Acta, 1798(12): 2240-8. [Abstract] [Full-text]
170. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals.
     Biochim Biophys Acta, 1798(12): 2190-200. [Abstract] [Full-text]
171. Cell-penetrating peptide exploited syndecans.
     Biochim Biophys Acta, 1798(12): 2258-65. [Abstract] [Full-text]
172. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery.
     Biochim Biophys Acta, 1798(12): 2201-8. [Abstract] [Full-text]
173. Happy birthday cell penetrating peptides: already 20 years.
     Biochim Biophys Acta, 1798(12): 2177-81. [Abstract] [Full-text]
174. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake.
     Biochim Biophys Acta, 1798(12): 2304-14. [Abstract] [Full-text]
175. Optical small animal imaging in the drug discovery process.
     Biochim Biophys Acta, 1798(12): 2266-73. [Abstract] [Full-text]
176. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma.
     J Cancer Res Clin Oncol, 136(12): 1929-35. [Abstract] [Full-text]
177. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
     J Cancer Res Clin Oncol, 136(12): 1845-51. [Abstract] [Full-text]
178. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
     J Cancer Res Clin Oncol, 136(12): 1901-13. [Abstract] [Full-text]
179. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells.
     Biochim Biophys Acta, 1798(12): 2274-85. [Abstract] [Full-text]
180. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
     Biochim Biophys Acta, 1798(12): 2296-303. [Abstract] [Full-text]
181. Peptide-mediated protein delivery-which pathways are penetrable?
     Biochim Biophys Acta, 1798(12): 2240-8. [Abstract] [Full-text]
182. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals.
     Biochim Biophys Acta, 1798(12): 2190-200. [Abstract] [Full-text]
183. Cell-penetrating peptide exploited syndecans.
     Biochim Biophys Acta, 1798(12): 2258-65. [Abstract] [Full-text]
184. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery.
     Biochim Biophys Acta, 1798(12): 2201-8. [Abstract] [Full-text]
185. Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts.
     Stroke, 41(11): 2587-91. [Abstract] [Full-text]
186. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA).
     Stroke, 41(11): 2612-7. [Abstract] [Full-text]
187. Acute basilar artery occlusion in the Basilar Artery International Cooperation Study: does gender matter?
     Stroke, 41(11): 2693-6. [Abstract] [Full-text]
188. Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.
     J Surg Oncol, 102(6): 649-55. [Abstract] [Full-text]
189. Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts.
     Stroke, 41(11): 2587-91. [Abstract] [Full-text]
190. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA).
     Stroke, 41(11): 2612-7. [Abstract] [Full-text]
191. Acute basilar artery occlusion in the Basilar Artery International Cooperation Study: does gender matter?
     Stroke, 41(11): 2693-6. [Abstract] [Full-text]
192. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial.
     Am J Hematol, 85(11): 863-7. [Abstract] [Full-text]
193. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
     Am J Hematol, 85(11): 877-81. [Abstract] [Full-text]
194. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
     J Surg Oncol, 102(6): 576-81. [Abstract] [Full-text]
195. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
     J Surg Oncol, 102(6): 663-70. [Abstract] [Full-text]
196. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
     J Pediatr Hematol Oncol, 32(8): e317-22. [Abstract] [Full-text]
197. All-transretinoic acid (ATRA) treatment-related pancarditis and severe pulmonary edema in a child with acute promyelocytic leukemia.
     J Pediatr Hematol Oncol, 32(8): e346-8. [Abstract] [Full-text]
198. Successful treatment of trilateral retinoblastoma with conventional and high-dose chemotherapy plus radiotherapy: a case report.
     J Pediatr Hematol Oncol, 32(8): e343-5. [Abstract] [Full-text]
199. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
     Jpn J Clin Oncol, 40(11): 1014-20. [Abstract] [Full-text]
200. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
     Jpn J Clin Oncol, 40(11): 1092-8. [Abstract] [Full-text]
201. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
     Jpn J Clin Oncol, 40(11): 1031-6. [Abstract] [Full-text]
202. Successful treatment of gastric adenocarcinoma in a Meckel's diverticulum with pemetrexed plus carboplatin.
     Jpn J Clin Oncol, 40(11): 1110-2. [Abstract] [Full-text]
203. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
     Pediatr Blood Cancer, 55(6): 1217-20. [Abstract] [Full-text]
204. Presumptive treatment for malaria is not justified in children receiving cancer chemotherapy.
     Pediatr Blood Cancer, 55(6): 1108-10. [Abstract] [Full-text]
205. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.
     Pediatr Blood Cancer, 55(6): 1083-8. [Abstract] [Full-text]
206. Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.
     Br J Cancer, 103(9): 1325-30. [Abstract] [Full-text]
207. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.
     Br J Cancer, 103(9): 1349-55. [Abstract] [Full-text]
208. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
     J Pediatr Hematol Oncol, 32(8): e317-22. [Abstract] [Full-text]
209. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
     Br J Cancer, 103(9): 1391-9. [Abstract] [Full-text]
210. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
     Br J Cancer, 103(9): 1343-8. [Abstract] [Full-text]
211. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
     Br J Cancer, 103(9): 1369-79. [Abstract] [Full-text]
212. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
     Br J Cancer, 103(9): 1415-21. [Abstract] [Full-text]
213. All-transretinoic acid (ATRA) treatment-related pancarditis and severe pulmonary edema in a child with acute promyelocytic leukemia.
     J Pediatr Hematol Oncol, 32(8): e346-8. [Abstract] [Full-text]
214. Successful treatment of trilateral retinoblastoma with conventional and high-dose chemotherapy plus radiotherapy: a case report.
     J Pediatr Hematol Oncol, 32(8): e343-5. [Abstract] [Full-text]
215. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.
     Br J Cancer, 103(9): 1331-4. [Abstract] [Full-text]
216. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
     Br J Cancer, 103(9): 1362-8. [Abstract] [Full-text]
217. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma.
     Pediatr Blood Cancer, 55(6): 1096-102. [Abstract] [Full-text]
218. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
     Pediatr Blood Cancer, 55(6): 1145-52. [Abstract] [Full-text]
219. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study.
     Pediatr Blood Cancer, 55(6): 1103-7. [Abstract] [Full-text]
220. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
     Jpn J Clin Oncol, 40(11): 1014-20. [Abstract] [Full-text]
221. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
     Jpn J Clin Oncol, 40(11): 1092-8. [Abstract] [Full-text]
222. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
     Jpn J Clin Oncol, 40(11): 1031-6. [Abstract] [Full-text]
223. Successful treatment of gastric adenocarcinoma in a Meckel's diverticulum with pemetrexed plus carboplatin.
     Jpn J Clin Oncol, 40(11): 1110-2. [Abstract] [Full-text]
224. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
     Pediatr Blood Cancer, 55(6): 1217-20. [Abstract] [Full-text]
225. Presumptive treatment for malaria is not justified in children receiving cancer chemotherapy.
     Pediatr Blood Cancer, 55(6): 1108-10. [Abstract] [Full-text]
226. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.
     Pediatr Blood Cancer, 55(6): 1083-8. [Abstract] [Full-text]
227. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma.
     Pediatr Blood Cancer, 55(6): 1096-102. [Abstract] [Full-text]
228. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
     Pediatr Blood Cancer, 55(6): 1145-52. [Abstract] [Full-text]
229. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study.
     Pediatr Blood Cancer, 55(6): 1103-7. [Abstract] [Full-text]
230. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
     Pediatr Blood Cancer, 55(6): 1217-20. [Abstract] [Full-text]
231. Presumptive treatment for malaria is not justified in children receiving cancer chemotherapy.
     Pediatr Blood Cancer, 55(6): 1108-10. [Abstract] [Full-text]
232. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.
     Pediatr Blood Cancer, 55(6): 1083-8. [Abstract] [Full-text]
233. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma.
     Pediatr Blood Cancer, 55(6): 1096-102. [Abstract] [Full-text]
234. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
     Pediatr Blood Cancer, 55(6): 1145-52. [Abstract] [Full-text]
235. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study.
     Pediatr Blood Cancer, 55(6): 1103-7. [Abstract] [Full-text]
236. Sustainability not all that matters: lessons from Cameroon.
     Arch Dis Child, 95(11): 928-30. [Abstract] [Full-text]
237. Effective and sustained delivery of hydrophobic retinoids to photoreceptors.
     Invest Ophthalmol Vis Sci, 51(11): 5958-64. [Abstract] [Full-text]
238. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.
     Invest Ophthalmol Vis Sci, 51(11): 5804-16. [Abstract] [Full-text]
239. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
     Pediatr Blood Cancer, 55(7): 1338-42. [Abstract] [Full-text]
240. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
     Pediatr Blood Cancer, 55(7): 1287-95. [Abstract] [Full-text]
241. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
     Pediatr Blood Cancer, 55(7): 1338-42. [Abstract] [Full-text]
242. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
     Pediatr Blood Cancer, 55(7): 1287-95. [Abstract] [Full-text]
243. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
     Int J Cancer, 128(1): 105-18. [Abstract] [Full-text]
244. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition.
     Int J Cancer, 128(1): 144-56. [Abstract] [Full-text]
245. Colorectal cancer risk in relation to antidepressant medication use.
     Int J Cancer, 128(1): 227-32. [Abstract] [Full-text]
246. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
     Int J Cancer, 128(1): 105-18. [Abstract] [Full-text]
247. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition.
     Int J Cancer, 128(1): 144-56. [Abstract] [Full-text]
248. Colorectal cancer risk in relation to antidepressant medication use.
     Int J Cancer, 128(1): 227-32. [Abstract] [Full-text]
249. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
     J Clin Oncol, 28(31): 4747-54. [Abstract] [Full-text]
250. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
     J Clin Oncol, 28(31): 4697-705. [Abstract] [Full-text]
251. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
     J Clin Oncol, 28(31): 4706-13. [Abstract] [Full-text]
252. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
     J Clin Oncol, 28(31): 4714-21. [Abstract] [Full-text]
253. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.
     Am J Physiol Gastrointest Liver Physiol, 299(5): G1068-77. [Abstract] [Full-text]
254. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.
     Nat Rev Drug Discov, 9(11): 843-56. [Abstract] [Full-text]
255. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease.
     Circ Res, 107(9): 1071-82. [Abstract] [Full-text]
256. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
     J Clin Oncol, 28(31): 4747-54. [Abstract] [Full-text]
257. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
     J Clin Oncol, 28(31): 4697-705. [Abstract] [Full-text]
258. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
     J Clin Oncol, 28(31): 4706-13. [Abstract] [Full-text]
259. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.
     Virology, 408(1): 80-8. [Abstract] [Full-text]
260. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
     J Clin Oncol, 28(31): 4714-21. [Abstract] [Full-text]
261. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.
     Am J Physiol Gastrointest Liver Physiol, 299(5): G1068-77. [Abstract] [Full-text]
262. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
     Blood, 116(17): 3171-9. [Abstract] [Full-text]
263. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
     Blood, 116(17): 3180-4. [Abstract] [Full-text]
264. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.
     Virology, 408(1): 80-8. [Abstract] [Full-text]
265. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.
     Virology, 408(1): 80-8. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.